Prognostic value of pre-treatment F-18-FDG PET-CT in patients with hepatocellular carcinoma undergoing radioembolization

Table 1 Patient, tumor, and treatment characteristics patients treated (n = 34)

		n (%)
FDG avidity	Yes	19 (56)
	No	15 (44)
ECOG-PS1	0	17 (50)
	1	14 (41)
	≥ 2	3 (9)
Gender	Female	9 (27)
	Male	25 (74)
Grade	G1	18 (53)
	G2	6 (18)
	G3	1 (3)
	Unknown	9 (27)
Presence of cirrhosis		20 (59)
Causes of cirrhosis (n = 20)	Viral hepatitis	12 (60)
	Hepatitis B	2 (10)
	Hepatitis C	10 (50)
	Alcohol	4 (20)
	NASH2	4 (20)
Prior treatment		15 (44)
Child pugh class	A	31 (91)
	B	3 (9)
BCLC stage3	A	4 (12)
	B	10 (29)
	C	19 (56)
	D	1 (3)
Tumor burden4	≤ 50%	29 (85)
	> 50%	5 (15)
Portal vein thrombosis		5 (15)
Extrahepatic disease		3 (9)
		Median (Range)
Age		68 (46-84)
PET SUVmax		4 (2-20)
Initial AFP		14 (1-186000)
Volume treated (mL)		1146 (191-2340)
Dose delivered (Gy)		126.6 (110.5-478.6)
Follow up (mo)		12 (1-63)

¹Eastern Cooperative Oncology Group Performance Status;

²Nonalcoholic Steatohepatitis;

³Barcelona Clinic Liver Cancer Staging classification;

⁴Proportional volumes of disease to whole liver based on volumetric imaging. AFP: Alpha feto protein.